Symptoms & Symptom Management
Diffuse intrapulmonary malignant mesothelioma (DIMM) mimicking interstitial lung disease. Ultrastructural analysis and the potential role of the Hedgehog signaling pathway
Ultrastructural Pathology 2025 [Link] Hector Chavarria, Mohamed Zedan, Osama Elkadi, Kurt Knowles, Guillermo Herrera Abstract Diffuse intrapulmonary malignant mesothelioma (DIMM) is a rare variant of epithelioid mesothelioma characterized by diffuse lung parenchymal involvement without a discrete pleural mass, often mimicking interstitial lung disease (ILD). We report a case of a 55-year-old male presenting with bilateral…
Read MoreEnhanced efficacy of immune checkpoint inhibitors with OK-432 in malignant pleural mesothelioma: A case report
Molecular and Clinical Oncology 2025 July 3 [Link] Kazuki Yamada, Takehiro Uemura, Aya Mukai, Tatsuya Tanaka, Ippei Sakakibara, Keima Ito, Yuta Mori, Kensuke Fukumitsu, Satoshi Fukuda, Yoshihiro Kanemitsu, Tomoko Tajiri, Yutaka Ito, Tetsuya Oguri, Akio Niimi Abstract Malignant pleural mesothelioma (MPM) is a rare and highly aggressive cancer with limited treatment options and poor prognosis.…
Read MoreThe Evolving Role of Chemotherapy in the Management of Pleural Malignancies: Current Evidence and Future Directions
Cancers 2025 June 25 [Link] Yuliya Semenova, Zhandos Burkitbayev, Nurtas Kalibekov, Alexandr Digay, Bakhyt Zhaxybayev, Oxana Shatkovskaya, Saule Khamzina, Dinara Zharlyganova, Zhuldyz Kuanysh, Almira Manatova Abstract Pleural malignancies represent a clinically devastating group of oncological disorders, most commonly arising from metastatic disease, with lung and breast cancers being the most frequent primary sites. Malignant pleural…
Read MoreMedical Thoracoscopy in Malignant Pleural Effusion
Cureus 2025 June 10 [Link] Amit K Rath, Sudarsan Pothal, Pallavi Bharadwaj Abstract Introduction: Malignant pleural effusion (MPE) is a common complication of advanced malignancies, often resulting in significant morbidity and impaired quality of life. In most cases, pleural fluid cytology remains negative. In the era of targeted cancer therapy, pathologists expect larger tissue samples.…
Read MoreFibulin-3 in plasma and pleural effusion as a biomarker of mesothelioma
Radiology and Oncology 2025 June 16 [Link] Katja Adamic, Mateja Marc Malovrh, Urska Bidovec Stojkovic, Ales Rozman Abstract Background: Malignant pleural mesothelioma (MPM) is a global health concern linked to asbestos exposure. In Slovenia, regions with high asbestos exposure rates make MPM a significant public health issue. Although thoracoscopic biopsy is the gold standard for…
Read MoreA Rare Case of Sarcomatoid-Type Localized Pleural Mesothelioma Derived From Visceral Pleura
Cureus 2025 March 30 [Link] Takayuki Kosaka, Seshiru Nakazawa, Rikuo Ushikubo, Takashi Ibe, Ken Shirabe Abstract A man in his 80s presented with shortness of breath. Chest CT scan showed pleural effusion and a mass in the right lower lobe. He had high inflammatory reaction and was diagnosed as having pulmonary suppuration with empyema. After…
Read MoreDiagnostic utility of pleuroscopic guided pleural biopsy versus pleural fluid cell block in the diagnosis of malignant pleural effusion
The Medical Journal of Malaysia 2025 March [Link] B H Ng, H J Low, N N N Abeed, C I Soo, M I Azmi, N S Sharil, R A Osman, M F A Hamid, A Y L Ban Abstract Introduction: Pleural biopsy using flex-rigid pleuroscopy or pleural effusion cell block analysis is useful for diagnosing…
Read MoreEx-Vivo Drug-Sensitivity Testing to Predict Clinical Response in Non-Small Cell Lung Cancer and Pleural Mesothelioma: A Systematic Review and Narrative Synthesis
Cancers 2025 March 14 [Link] Jenny Zipprick, Enes Demir, Hanna Krynska, Sıla Köprülüoğlu, Katharina Strauß, Marcus Skribek, Rita Hutyra-Gram Ötvös, Annica K B Gad, Katalin Dobra Abstract Background/objectives: Non-small cell lung cancer and pleural mesothelioma are among the most lethal and therapy-resistant tumors in humans. These tumors are diagnosed late, frequently present pleural effusion and…
Read MoreNew soluble CSF-1R-dimeric mutein with enhanced trapping of both CSF-1 and IL-34 reduces suppressive tumor-associated macrophages in pleural mesothelioma
Journal for Immunotherapy for Cancer 2025 March 17 [Link] Noémie Joalland, Agnès Quéméner, Sophie Deshayes, Romain Humeau, Mike Maillasson, Héloïse LeBihan, Apolline Salama, Judith Fresquet, Séverine Remy, Erwan Mortier, Christophe Blanquart, Carole Guillonneau, Ignacio Anegon Abstract Background: Colony stimulating factor-1 receptor (CSF-1R) and its ligands CSF-1 and interleukin (IL)-34 have tumorigenic effects through both induction…
Read MoreSarcomatoid pleural mesothelioma evaluated using diffusion-weighted whole-body imaging with background body signal suppression
Respiratory Investigation 2025 May [Link] Ryosuke Kinoshita, Norihisa Takeda, Hiroko Kiyotoshi, Masahiro Sugihara, Mamiko Kuriyama, Makoto Nakao, Takuji Tsuyuki, Hideki Muramatsu Abstract An 83-year-old man with a history of asbestos exposure presented with dyspnea. Thoracic computed tomography showed right-sided pleural effusion and heterogeneous pleural thickening with calcified plaques. Thoracentesis revealed exudative fluid, and the cytology…
Read More